Search for a trial

Effects of ziltivekimab versus placebo on cardiovascular outcomes in participants with established atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation

This study has been transitioned to CTIS with ID 2023-506926-35-00 check the CTIS register for the current data. The primary objective is to demonstrate the superiority of ziltivekimab 15 mg s.c. once-monthly in reducing the risk of MACE (as defined…

The effect of intradialytic supplementation in chronic hemodialysis patients; a pilot study

The primary objective of this pilot study is the feasibility of prolonged intra-dialytic creatine supplementation. The secondary objectives of this pilot study are to study the safety of prolonged intra-dialytic creatine supplementation for dialysis…

Tirzepatide Study of Renal Function in People with Overweight or Obesity and
Chronic Kidney Disease with or without Type 2 Diabetes: Focus on Kidney
Hypoxia in Relation to Fatty Kidney Disease using Multiparametric Magnetic
Resonance Imaging (TREASURE-CKD)

This study has been transitioned to CTIS with ID 2023-506082-60-00 check the CTIS register for the current data. The objective of this study is to investigate the mechanism(s) of action of tirzepatide in the kidney, in participants who are…

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of KBP-5074, a Mineralocorticoid Receptor Antagonist, in Subjects with Uncontrolled Hypertension Who Have Moderate or Severe (Stage 3b/4) Chronic Kidney Disease

The primary objective of this study is to evaluate the efficacy and durability of KBP-5074 in reducing SBP.The primary endpoint for efficacy is change in seated trough cuff SBP from baseline to Week 12.The second key endpoint for durability is…

Evaluation of GeranylGeranylAcetone in heart failure with preserved ejection fraction

Primary objectivesTo study whether Geranyl-Geranyl Acetone (GGA) reduces left ventricular (LV) diastolic dysfunction in patients with HFpEF compared to placebo (and to assess/confirm its effectiveness and safety in patients with HFpEF)Secondary…

A Phase 1 Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate
the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a
Single Dose of DCR-PHXC in Patients with Primary Hyperoxaluria Type 3

Primary objective:To evaluate the safety and tolerability of a single dose of DCR-PHXC in patients with PH3Secondary objectives:To characterize the plasma PK of a single dose of DCR-PHXC in patients with PH3To assess the efficacy of a single dose of…

Multicenter, Randomized, Double-blind, Placebo-controlled Two Stage Study to Characterize the Efficacy, Safety, Tolerability and Pharmacokinetics of GZ/SAR402671 in Patients at risk of Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD)

The aim of the research is to determine the effect of GZ/SAR402671 on the total growth in kidney volume (total kidney volume, TKV) in patients with ADPKD. This research also looks at the effectiveness of GZ / SAR402671 in slowing down the decrease…

A Phase 2 Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of DCR-PHXC Solution for Injection (subcutaneous use) in Patients with Primary Hyperoxaluria

Primary:To assess the efficacy of DCR-PHXC in reducing urinary oxalate burden in patients with PH (types 1 and 2)Key Secondary:To assess the efficacy of DCR-PHXC in reducing urinary oxalate burden over time in patients with PHSecondary:1. To…

A phase III double-blind, randomized study to evaluate the long-term
efficacy and safety of Oxabact® in patients with primary hyperoxaluria

Primary:- To evaluate the efficacy of Oxabact® following 52 weeks treatment in patients with maintained kidney function but below the lower limit of the normal range (eGFR < 90 ml/min/1.73 m2) and a total plasma oxalate concentration &gt…

\u201cA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Belimumab plus Standard of Care versus Placebo plus Standard of Care in Adult Subjects with Active Lupus Nephritis\u201d (protocol HGS1006-C1121)

* To evaluate the efficacy of belimumab in combination with standard of care in adult subjects with lupus nephritis Class III, IV, or V using the 2003 ISN/RPS criteria. * To assess the safety and tolerability of belimumab plus standard of care…

A phase 3 randomized, open-label (sponsor-blind), active-controlled, parallel-group, multi-center, event driven study in dialysis subjects with anemia associated with chronic kidney disease to evaluate the safety and efficacy of daprodustat compared to recombinant human erythropoietin, following a switch from erythropoietin-stimulating agents.;Anemia Studies in CKD: Erythropoiesis via a Novel PHI Daprodustat-Dialysis (ASCEND-D)

Co-primary (tested in parallel for non-inferiority):- To compare daprodustat to rhEPO for CV safety (non-inferiority)- To compare daprodustat to rhEPO for Hgb efficacy(non-inferiority)

A phase 3 randomized, open-label (sponsor-blind), active-controlled, parallel-group, multi-center, event driven study in non-dialysis subjects with anemia associated with chronic kidney disease to evaluate the safety and efficacy of daprodustat compared to darbepoetin alfa;Anemia Studies in CKD: Erythropoiesis via a Novel PHI Daprodustat-Non-Dialysis (ASCEND-ND)

Co-primary (tested in parallel for non-inferiority):-To compare daprodustat to darbepoetin alfa for CV safety (non-inferiority)-To compare daprodustat to darbepoetin alfa for Hgb efficacy(non-inferiority)

The effects of protein ingestion and exercise on plasma and dialysate amino acid concentrations during hemodialysis

To assess the effects of intradialytic exercise and protein ingestion on amino acid loss into the dialysate and plasma total amino acid concentrations.

Phase 2 randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety and efficacy of Reltecimod as compared to placebo in addition to standard of care in patients with sepsis-associated acute kidney injury (SA-AKI)

Primary objective:* To compare the rates of complete recovery (alive, free of dialysis and return of serum creatinine to <150% of reference baseline; equivalent to acute kidney disease (AKD) category 0) at Day 14 between the Reltecimod-…

Treatment of vascular stiffness in patients with autosomal dominant polycystic kidney disease

This study has been transitioned to CTIS with ID 2024-512544-27-00 check the CTIS register for the current data. We aim to investigate if arterial stiffness is exacerbated due to a high-salt diet in patients with ADPKD. We also intend to explore…

The protective effect of Masquelier*s® French Pine Bark Extract with Original OPC in half-marathon runners using a single low dose of ibuprofen

In the present study we aim to assess the efficacy of a 14-days intervention with monomeric and oligomeric flavanols from Vitis vinifera seeds and Pinus pinaster bark (MOF-VVPB) which are the active principle in Masquelier*s® French Pine Bark…